Effect of omega-3 polyunsaturated fatty acids on blood lipid profile, leptin level and endothelial function in patients with ischemic heart disease in combination with non-alcoholic steatosis of the liver
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: to study the effect of omega-3 polyunsaturated essential fatty acids (PUFAs) on leptin level, lipid profile of blood and endothelial function in patients with coronary heart disease (CHD) in combination with non-alcoholic steatosis of the liver.
Materials and methods. 44 men were examined. Group А consisted of 24 patients aged 55–72 (median 64 [59,0; 69,0] years) with CHD in combination with non-alcoholic steatosis of the liver, group В – 18 patients aged 53–70 (median 59,7 [56,0, 65,0] years) with CHD without non-alcoholic steatosis. Blood lipid profile, leptin level and functional state of vascular endothelium were defined in all patients.
Results. After the treatment with omega-3 PUFAs 2000 mg for 2 months in patients with CHD in combination with steatosis of the liver, a decrease in the level of triglycerides (TG) (by 42%; p=0,02), very low density lipoproteins (VLDL-C) (by 15%; p=0,02), leptin level (by 13%; p=0,002), C-reactive protein (CRP) (by 45%; p=0,02), increase of high-density lipoprotein levels (HDL-C) (by 3%; p=0,02) and improvement in endothelial function (by 26%; p<0,05) were determined.
Conclusion. Using of omega-3 PUFAs in the treatment of patients with CHD in combination with liver steatosis as a secondary prevention provides a reduction in the level of TG, VLDL-C, leptin, and increase in HDL-C. The positive dynamics of indicators of endothelial function and CRP level and the tendency to decrease of blood glucose levels were revealed, which indicates the presence of pleiotropic effects of omega-3 PUFAs.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Гречаник М.М. Кардіогемодинаміка та показники пружно-еластичних властивостей каротидних артерій у хворих з ішемічною хворобою серця в поєднанні з неалкогольним стеатозом печінки / Гречаник М.М //Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії. – 2017. – № 3 (59). – С. 101–105
Курята А.В. Атеросклероз магистральных артерий головы, уровень лептина и постпрандиальная гипертриглицеридемия у пациентов с ишемической болезнью сердца в сочетании с неалкогольной жировой болезнью печени в зависимости от индекса массы тела / Курята А.В., Гречаник М.М. // Український терапевтичний журнал. – 2016. – № 4 (51). – С. 55–62.
Курята А.В. Взаимосвязь липидного спектра крови, уровня системного воспаления и массы тела у пациентов с ишемической болезнью сердца в сочетании с неалкогольной жировой болезнью печени и их динамика в условиях вторичной профилактики / Курята А.В., Гречаник М.М. // Медичні перспективи. – 2014. – Т. Х1Х (4). – С. 103–111.
Сиренко Ю.Н. Влияние омега-3-полиненасыщенных жирных кислот на функциональные свойства сосудов у больных артериальной гипертензией / Сиренко Ю.Н., Кушнир С.Н. // Український медичний часопис. – 2012. – № 4 (90) – С. 117–120.
Backes J. The clinical relevance of omega-3 fatty acids in the management of Hypertriglyceridemia / Backes J, Anzalone D, Hilleman D, et al // Lipids in Health and Disease. – 2016. – Vol. 15(1):118. https://doi.org/10.1186/s12944-016-0286-4
Ballestri S. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease / Ballestri S., Lonardo A., Bonapace S., Byrne C., Loria P., Targher G.// World J Gastroenterol. – 2014. – Vol. 20 (7). – Р. 1724–1745. https://doi.org/10.3748/wjg.v20.i7.1724
Bril F. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD / Bril F, John J., Sninsky Arthur M., Baca H. et al. // The Journal of Clinical Endocrinology & Metabolism. – 2016. – Vol. 101, № 2. – P. 644–652. https://doi.org/10.1210/jc.2015-3111
Catapano A.L. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias / Catapano AL, Graham I, De Backer G, et al. // European Heart Journal. – Vol. 37, № 39. – P. 2999–3058. https://doi.org/10.1093/eurheartj/ehw272
Cicero A.F. Lipid-lowering and antiinflammatory effects of omega 3 ethyl esters and krill oil: a randomized, crossover, clinical trial / Cicero A.F., Rosticci M., Morbini M. et al // Arch Med Sci. – 2016. – Vol. 12 (3). – Р. 507–12. https://dx.doi.org/10.5114%2Faoms.2016.59923
Celermajer D. Endothelial dysfunction: does it matter? It is relevant? // Journal American Collage Cardiology. – 1997. – Vol. 30. – P. 325–333. https://doi.org/10.1016/S0735-1097(97)00189-7
Kusunoki C. Omega-3 polyunsaturated fatty acid has an anti-oxidant effect via the Nrf-2/HO-1 pathway in 3T3-L1 adipocytes. / Kusunoki C, Yang L, Yoshizaki T, et al. // Biochem Biophys Res Commun. – 2013. – Vol. 430. – Р. 225–30. https://doi.org/10.1016/j.bbrc.2012.10.115
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice // European Heart Journal. – 2016. – Vol. 37, № 29. – P. 2315–2381. https://doi.org/10.1093/eurheartj/ehw106
Sattar N. Leptin and coronary heart disease: prospective study and systematic review / Sattar N, Wannamethee G, Sarwar N, et al.// J Am Coll Cardiol. – 2009. – Vol. 3753 (2). – Р. 167–75. https://doi.org/10.1016/j.jacc.2008.09.035
Weintraub H. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options / Weintraub H. // Atherosclerosis. – 2013. – Vol. 230 (2). – Р. 381–9. https://doi.org/10.1016/j.atherosclerosis.2013.07.041
Yang,H. Leptin concentration and risk of coronary heart disease and stroke: A systematic review and meta-analysis / Yang H Guo, W Jie Li, Shengli Cao et al // PLoS One. – 2017. – Vol. 12 (3):e0166360. https://doi.org/10.1371/journal.pone.0166360
Zeng R. Association of leptin levels with pathogenetic risk of coronary heart disease and stroke: a meta-analysis / Zeng R., Xu Chun-Hua, Yuan-Ning Xu, Ya-li Wang, Mian Wang // Arq Bras Endocrinol Metabol. – 2014. – Vol. 58 (8). – P. 817–23. http://dx.doi.org/10.1590/0004-2730000003390
